IMCR vs. CRSP
IMCR (Immunocore Holdings plc) and CRSP (CRISPR Therapeutics AG) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, IMCR returned -6.01%/yr vs -14.40%/yr for CRSP. At a 0.32 correlation, their price movements are largely independent.
Performance
IMCR vs. CRSP - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, IMCR achieves a -17.46% return, which is significantly lower than CRSP's -0.69% return.
IMCR
- 1D
- -3.08%
- 1M
- 0.46%
- YTD
- -17.46%
- 6M
- -24.37%
- 1Y
- -25.85%
- 3Y*
- -20.19%
- 5Y*
- -6.01%
- 10Y*
- —
CRSP
- 1D
- 0.12%
- 1M
- -2.80%
- YTD
- -0.69%
- 6M
- -6.98%
- 1Y
- 36.91%
- 3Y*
- -7.12%
- 5Y*
- -14.40%
- 10Y*
- —
IMCR vs. CRSP - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
IMCR Immunocore Holdings plc | -17.46% | 17.66% | -56.82% | 19.71% | 66.68% | -20.74% |
CRSP CRISPR Therapeutics AG | -0.69% | 33.23% | -37.12% | 54.00% | -46.36% | -55.11% |
Correlation
The correlation between IMCR and CRSP is 0.29, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.29 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.29 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.32 |
Correlation (All Time) Calculated using the full available price history since Feb 8, 2021 | 0.32 |
Fundamentals
IMCR:
$1.52B
CRSP:
$5.00B
IMCR:
-$0.37
CRSP:
-$6.24
IMCR:
3.79
CRSP:
1.16K
IMCR:
3.85
CRSP:
2.76
IMCR:
$385.76M
CRSP:
$4.10M
IMCR:
$381.15M
CRSP:
-$171.17M
IMCR:
-$3.01M
CRSP:
-$509.21M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
IMCR vs. CRSP — Risk / Return Rank
IMCR
CRSP
IMCR vs. CRSP - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Immunocore Holdings plc (IMCR) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IMCR | CRSP | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.29 | ||
| Sortino ratioReturn per unit of downside risk | -2.18 | ||
| Omega ratioGain probability vs. loss probability | 0.90 | 1.15 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | -0.85 | 0.88 | -1.73 |
| Martin ratioReturn relative to average drawdown | -1.52 | 1.49 | -3.01 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| IMCR | CRSP | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.69 | 0.60 | -1.29 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.12 | -0.24 | +0.12 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.14 | 0.23 | -0.36 |
Drawdowns
IMCR vs. CRSP - Drawdown Comparison
The maximum IMCR drawdown since its inception was -67.45%, smaller than the maximum CRSP drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for IMCR and CRSP.
Loading charts...
Drawdown Indicators
| IMCR | CRSP | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.45% | -85.11% | +17.66% |
Max Drawdown (1Y)Largest decline over 1 year | -30.60% | -42.25% | +11.65% |
Max Drawdown (3Y)Largest decline over 3 years | -67.45% | -64.91% | -2.54% |
Max Drawdown (5Y)Largest decline over 5 years | -67.45% | -80.68% | +13.23% |
Current DrawdownCurrent decline from peak | -61.98% | -75.20% | +13.22% |
Average DrawdownAverage peak-to-trough decline | -36.56% | -49.17% | +12.61% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.42% | 24.92% | -7.50% |
Volatility
IMCR vs. CRSP - Volatility Comparison
The current volatility for Immunocore Holdings plc (IMCR) is 11.53%, while CRISPR Therapeutics AG (CRSP) has a volatility of 14.90%. This indicates that IMCR experiences smaller price fluctuations and is considered to be less risky than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| IMCR | CRSP | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.53% | 14.90% | -3.37% |
Volatility (6M)Calculated over the trailing 6-month period | 26.30% | 42.49% | -16.19% |
Volatility (1Y)Calculated over the trailing 1-year period | 37.66% | 61.68% | -24.02% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 50.37% | 60.46% | -10.09% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 54.40% | 64.27% | -9.87% |
Dividends
IMCR vs. CRSP - Dividend Comparison
Neither IMCR nor CRSP has paid dividends to shareholders.
Financials
IMCR vs. CRSP - Financials Comparison
This section allows you to compare key financial metrics between Immunocore Holdings plc and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
IMCR and CRSP have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRSP has higher volatility (14.90%) compared to IMCR (11.53%). In terms of maximum drawdown, IMCR dropped -67.45% vs CRSP's -85.11%.
CRSP currently has the higher Sharpe Ratio (0.60 vs -0.69), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for IMCR and CRSP
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer